ESR1 and cancer: Ranking number one in women’s cancer-related deaths worldwide, BC is a heterogeneous disease covering four different subtypes characterized by distinct molecular and clinical phenotypes, among which the luminal estrogen receptor α positive (Erα+) subtype [6] is the most frequent, representing up to 80% of diagnosed cases [7].